Mentice (MNTC) Q3 2024 earnings summary

Executive summary

• Q3 net sales were SEK 57.7–58 million, down about 10% year-over-year, mainly due to weaker performance in the Americas and EMEA, while APAC showed growth.

• EBITDA for Q3 was -6.2 MSEK, with year-to-date EBITDA at break-even, compared to a 21–22% margin last year.

• Operational cash flow was positive year-to-date but negative for the quarter; cash at period end was SEK 46 million.

• Two major VIST orders from a top 20 global Med Tech company were secured after the quarter, expected to impact Q4 and drive future growth.

• Significant investments in product development and organizational growth continued, with headcount rising to 133 from 114.

Financial highlights

• Q3 net sales decreased by 9.7% to 57.7 MSEK; nine-month net sales were flat at 204.0 MSEK.

• APAC region sales increased by 4% to SEK 40 million in Q3 and 56% for the nine months; Americas and EMEA declined by 19% and 19.4% respectively.

• Physical SIM and Ankyras product areas grew 25.5–26% year-over-year.

• Order intake for Q3 was SEK 61 million, down 6% year-over-year; order book decreased 9% to SEK 117 million.

• Gross margin improved to 90.1% in Q3 (from 86.5%); nine-month gross margin was 88.6%.

Outlook and guidance

• Financial targets remain: 20–30% annual net sales growth and 20% EBITDA within three years, with a long-term target of 30%.

• Management reiterates confidence in the business pipeline and expects positive developments across all regions.

• SaaS transition expected to reduce sales volatility and drive recurring revenue.

• Two large Q4 orders are expected to be delivered mainly in the fourth quarter, supporting a stronger finish to the year.